.jpg)
Global investment firm KKR has signed a definitive agreement to acquire a controlling stake in Healthcare Global Enterprises (HCG) from CVC Asia V for $400 million (₹3,465 crore). This move strengthens KKR’s footprint in India’s healthcare sector, particularly in oncology care.
Under the agreement, KKR will acquire up to 54% equity at ₹445 per share and will also make an open offer to public shareholders, potentially increasing its stake to 77%. Upon completion, KKR will assume sole control of HCG’s operations, while Founder Dr. BS Ajaikumar transitions to Non-Executive Chairman, focusing on clinical advancements, research, and academic excellence.
Founded in 1989, HCG is India’s leading cancer care network, operating 25 hospitals across 19 cities, with a robust infrastructure of 2,500 beds, 100 operating theaters, and 40 linear accelerator machines. The deal, expected to close by Q3 2025, aligns with KKR’s strategy to enhance medical infrastructure and oncology services in India